New hope for Tough-to-Treat colon cancer? early trial launches
NCT ID NCT07500298
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This early-phase study is testing whether a new drug called SAR445877, when added to standard chemotherapy and a targeted therapy, is safe for people with advanced colorectal cancer that hasn't spread widely yet. About 41 adults will take part. The main goal is to find any side effects and see if the combination can help control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEVACIZIMAB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can mindfulness together ease the burden of advanced cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can a targeted pill boost Chemo's power against a rare blood cancer?
- Mini-Tumors grown in a dish could guide chemo choices for advanced colorectal cancer
- Blood test may reveal hidden cancer spread without scans